CA2410000A1 - Compositions and methods comprising plasmid dna for wound healing and for repairing and regenerating tissue - Google Patents
Compositions and methods comprising plasmid dna for wound healing and for repairing and regenerating tissue Download PDFInfo
- Publication number
- CA2410000A1 CA2410000A1 CA002410000A CA2410000A CA2410000A1 CA 2410000 A1 CA2410000 A1 CA 2410000A1 CA 002410000 A CA002410000 A CA 002410000A CA 2410000 A CA2410000 A CA 2410000A CA 2410000 A1 CA2410000 A1 CA 2410000A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- cells
- biopolymer
- regeneration
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 20
- 239000013612 plasmid Substances 0.000 title claims abstract 13
- 239000000203 mixture Substances 0.000 title claims abstract 6
- 230000029663 wound healing Effects 0.000 title claims abstract 5
- 230000001172 regenerating effect Effects 0.000 title claims abstract 3
- 229920001222 biopolymer Polymers 0.000 claims abstract 12
- 230000008929 regeneration Effects 0.000 claims abstract 10
- 238000011069 regeneration method Methods 0.000 claims abstract 10
- 239000006285 cell suspension Substances 0.000 claims abstract 8
- 230000008092 positive effect Effects 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract 5
- 210000001519 tissue Anatomy 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- 230000007547 defect Effects 0.000 claims 7
- 206010052428 Wound Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000003416 augmentation Effects 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 210000002510 keratinocyte Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000004116 schwann cell Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Materials For Photolithography (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gyroscopes (AREA)
- Sorption Type Refrigeration Machines (AREA)
Abstract
The present invention relates to a method of preparing a composition for wound healing, and for repairing and regenerating human and animal tissue, said method comprising the following steps: a) providing a plasmid DNA in substantially pure form, which encodes a gene that has a positive effect on the progression of the regeneration of the tissue, b) providing a component/components of a self-hardening bio-polymer, and c) providing a cell suspension with cells which promote regeneration, characterized in that components (a), (b) and (c) are incubated with each other simultaneously or successively so that the plasmid and the cell suspension are obtained homogenously distributed in one of the biopolymer components.
Claims (22)
1. A method of preparing a composition for wound healing, and for repairing and regenerating mammalian tissue, said method comprising the following steps:
a. providing a plasmid DNA in substantially pure form which encodes a gene that has a positive effect on the progression of the regeneration of the tissue, b. providing a component/components of a self-hardening biopolymer, and c. providing a cell suspension with cells which promote regeneration, characterized in that components (a), (b) and (c) are incubated with each other simultaneously or successively so that the plasmid and the cell suspension are obtained homogenously distributed in one of the biopolymer components.
a. providing a plasmid DNA in substantially pure form which encodes a gene that has a positive effect on the progression of the regeneration of the tissue, b. providing a component/components of a self-hardening biopolymer, and c. providing a cell suspension with cells which promote regeneration, characterized in that components (a), (b) and (c) are incubated with each other simultaneously or successively so that the plasmid and the cell suspension are obtained homogenously distributed in one of the biopolymer components.
2. A method according to claim 1, characterized in that the biopolymer is selected from a fibrin adhesive, collagen, gelatin, alginate, hyaluronic acid, polysaccharide, organic polymer or derivatives thereof or combinations thereof, respectively.
3. A method according to claim 1 or 2, characterized in that the biopolymer is a fibrin adhesive.
4. A method according to any one of claims 1 to 3, characterized in that the plasmid and the cells are in the thrombin component of the fibrin adhesive.
5. A method according to any one of claims 1 to 3, characterized in that the biopolymer is provided in a liquid or lyophilized form.
6. A method according to any one of claims 1 to 5, characterized in that the ratio of plasmid to biopolymer component is 5-25 µg/ml, preferably 10-20 µg/ml.
7. A method according to any one of claims 1 to 6, characterized in that the ratio of plasmid to biopolymer component is 25-100 µg/ml, preferably around 50 µg/ml.
8. A method according to any one of claims 1 to 7, characterized in that the ratio is from 25,000-75,000 cells/µg of plasmid.
9. A method according to any one of claims 1 to 7, characterized in that the ratio is 75,000-100,000 cells/µg of plasmid, preferably around 50,000.
10. A method according to any one of the preceding claims, characterized in that the number of cells per ml of biopolymer component is 200,000 to 5 000,000, preferably 3 000,000.
11. A method according to any one of the preceding claims, characterized in that the cell suspension is a suspension of cells selected from keratinocytes, chondrocytes, fibroblasts, epithelial cells, endothelial cells, Schwann cells, osteoblasts and osteoclasts.
12. Transfection system containing a plasmid DNA in substantially pure form which codes for a gene that has a positive effect on the progression of regeneration of the tissue, a component of a self-hardening biopolymer and a cell suspension with cells promoting the regeneration and which does not contain any further transfection-promoting or transfection-mediating substances.
13. A pharmaceutical composition containing a plasmid DNA in substantially pure form which codes for a gene that has a positive effect on the progression of the regeneration of tissue, components of a self-hardening biopolymer, a cell suspension with cells which promote the regeneration and, optionally, a further pharmaceutically acceptable carrier, and no further transfection-promoting or transfection-mediating substances.
14. A therapeutical kit for treating tissue defects, comprising:
- a plasmid DNA in substantially pure form, which encodes a gene that has a positive effect on the progression of the regeneration of the tissue, - components of a self-hardening biopolymer, and - a cell suspension comprising cells which promote said regeneration, and which does not contain any further transfection-promoting or transfection-mediating substances.
- a plasmid DNA in substantially pure form, which encodes a gene that has a positive effect on the progression of the regeneration of the tissue, - components of a self-hardening biopolymer, and - a cell suspension comprising cells which promote said regeneration, and which does not contain any further transfection-promoting or transfection-mediating substances.
15. A therapeutical kit containing a composition obtainable according to a method according to any one of claims 1 to 11.
16. The use of a transfection system, of the pharmaceutical composition or of the therapeutical kit according to any one of claims 12 to 15 for the treatment of tissue defects.
17. The use according to claim 16 for the treatment of burn wounds, bone, muscle, nerve or cartilage defects, chronic wounds or tissue augmentations, preferably for wound healing in the skin.
18. The use according to any one of claims 16 to 17, wherein the composition is sprayed onto the tissue defect.
19. The use of a gel containing the pharmaceutical composition obtainable according to a method according to any one of claims 1 to 11 for the treatment of tissue defects.
20. Method for the treatment of tissue defects using a composition prepared according to any one of claims 1-11, the system according to claim 12, the pharmaceutical composition according to claim 13 or the kit according to claim 14 or 15.
21. Method for treatment according to claim 20 for treating burn wounds, bone, muscle, nerve or cartilage defects, chronic wounds or tissue augmentations.
22. Method according to claim 20 or 21 for wound healing in the skin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10025609.0 | 2000-05-24 | ||
| DE10025609A DE10025609A1 (en) | 2000-05-24 | 2000-05-24 | Transfection system |
| PCT/EP2001/005937 WO2001089593A1 (en) | 2000-05-24 | 2001-05-23 | Transfection system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2410000A1 true CA2410000A1 (en) | 2001-11-29 |
| CA2410000C CA2410000C (en) | 2011-01-25 |
Family
ID=7643316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2410000A Expired - Fee Related CA2410000C (en) | 2000-05-24 | 2001-05-23 | Compositions and methods comprising plasmid dna for wound healing and for repairing and regenerating tissue |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040043007A1 (en) |
| EP (1) | EP1292340B1 (en) |
| JP (3) | JP4951185B2 (en) |
| AT (1) | ATE306946T1 (en) |
| AU (2) | AU2001260328A1 (en) |
| CA (1) | CA2410000C (en) |
| DE (2) | DE10025609A1 (en) |
| ES (1) | ES2252234T3 (en) |
| WO (1) | WO2001089593A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007040252A1 (en) * | 2006-09-11 | 2008-06-12 | Gerlach, Jörg, Prof. Dr. | Device for electronically flow-controlled distribution of tissue regenerating cell in sterile suspension across an area for further growth comprises electronically pressure/flow controlled spray head enabling controlled pump driven spraying |
| US8387282B2 (en) | 2010-04-26 | 2013-03-05 | Nike, Inc. | Cable tightening system for an article of footwear |
| DE102011100450B8 (en) | 2011-04-27 | 2013-10-17 | Jörg Gerlach | Apparatus for spraying cells, making the apparatus, method for spraying with the apparatus and a cell suspension sprayed with the apparatus |
| ES2399273B1 (en) * | 2011-09-13 | 2014-01-28 | Universidad Politécnica De Valencia | ESTUCO FOR THE CONSERVATION AND RESTORATION OF BONE MATERIALS. |
| JP6907244B2 (en) | 2016-06-14 | 2021-07-21 | レノバケア・サイエンシズ・コーポレイション | Modular device for cell spraying |
| CN112957485A (en) * | 2021-02-22 | 2021-06-15 | 上海药明生物技术有限公司 | Plasmid DNA sterilization treatment method based on pasteurization, obtained sterilized plasmid DNA and application |
| CN119193700A (en) * | 2024-11-15 | 2024-12-27 | 华南农业大学 | A liposome transfection method for chicken primordial gonad cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661132A (en) * | 1989-12-14 | 1997-08-26 | Auragen, Inc. | Wound healing |
| JPH08501203A (en) * | 1992-06-03 | 1996-02-13 | ケイス・ウエスタン・リザーブ・ユニバーシティー | Bandage for continuous application of bioactive substances |
| US5962427A (en) * | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
| DE19521324C1 (en) * | 1995-06-12 | 1996-10-31 | Immuno Ag | Tissue adhesive and use thereof as a hemostatic |
| DE19716098A1 (en) * | 1997-04-17 | 1998-10-22 | Univ Ludwigs Albert | Fibroblasts containing a foreign gene composition for treating wounds |
| US20020064517A1 (en) * | 1998-04-30 | 2002-05-30 | Stewart A. Cederholm-Williams | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
| NZ528340A (en) * | 1998-12-02 | 2005-07-29 | Bristol Myers Squibb Co | Spray delivery of cells |
-
2000
- 2000-05-24 DE DE10025609A patent/DE10025609A1/en not_active Ceased
-
2001
- 2001-05-23 AU AU2001260328A patent/AU2001260328A1/en not_active Abandoned
- 2001-05-23 JP JP2001585834A patent/JP4951185B2/en not_active Expired - Fee Related
- 2001-05-23 DE DE60114193T patent/DE60114193T2/en not_active Expired - Lifetime
- 2001-05-23 CA CA2410000A patent/CA2410000C/en not_active Expired - Fee Related
- 2001-05-23 AT AT01934009T patent/ATE306946T1/en active
- 2001-05-23 EP EP01934009A patent/EP1292340B1/en not_active Expired - Lifetime
- 2001-05-23 US US10/296,087 patent/US20040043007A1/en not_active Abandoned
- 2001-05-23 WO PCT/EP2001/005937 patent/WO2001089593A1/en active IP Right Grant
- 2001-05-23 ES ES01934009T patent/ES2252234T3/en not_active Expired - Lifetime
-
2007
- 2007-03-28 AU AU2007201342A patent/AU2007201342B2/en not_active Ceased
-
2008
- 2008-05-20 JP JP2008132143A patent/JP2008208145A/en not_active Withdrawn
-
2011
- 2011-10-31 JP JP2011239632A patent/JP2012021034A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007201342B2 (en) | 2009-01-08 |
| WO2001089593A1 (en) | 2001-11-29 |
| JP2008208145A (en) | 2008-09-11 |
| AU2007201342A1 (en) | 2007-04-19 |
| CA2410000C (en) | 2011-01-25 |
| ES2252234T3 (en) | 2006-05-16 |
| JP2004531453A (en) | 2004-10-14 |
| US20040043007A1 (en) | 2004-03-04 |
| AU2001260328A1 (en) | 2001-12-03 |
| ATE306946T1 (en) | 2005-11-15 |
| JP4951185B2 (en) | 2012-06-13 |
| JP2012021034A (en) | 2012-02-02 |
| EP1292340A1 (en) | 2003-03-19 |
| DE60114193D1 (en) | 2006-03-02 |
| DE10025609A1 (en) | 2001-12-13 |
| DE60114193T2 (en) | 2006-11-23 |
| EP1292340B1 (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Applications of decellularized extracellular matrix in bone and cartilage tissue engineering | |
| US20220040371A1 (en) | Photoactivated crosslinking of a protein or peptide | |
| Sims et al. | Tissue engineered neocartilage using plasma derived polymer substrates and chondrocytes | |
| Li et al. | Biopolymer/calcium phosphate scaffolds for bone tissue engineering | |
| US7993679B2 (en) | Flowable wound matrix and its preparation and use | |
| US6730299B1 (en) | Adhesive protein foam for surgical and/or therapeutic uses | |
| EP2514445A2 (en) | Bioactive hydrogel compositions | |
| SE1251043A1 (en) | Hydrogel coated scaffold | |
| RU2010142988A (en) | METHOD AND COMPOSITION FOR TISSUE REGENERATION USING STEM OR BONE MARROW CELLS | |
| WO2013059089A1 (en) | Bone pastes comprising biofunctionalized calcium phosphate cements with enhanced cell functions for bone repair | |
| Hofmann et al. | Bioactive scaffolds for the controlled formation of complex skeletal tissues | |
| AU2007201342B2 (en) | Transfection System | |
| AU2006207618A1 (en) | Hyaluronic acid derivative and neural stem cells for SCI and PNT regeneration | |
| JP2004531453A5 (en) | ||
| TWI461416B (en) | Cell Tissue Adhesive | |
| WO2019151736A1 (en) | Composition for bone grafting, comprising nucleic acids, bone graft material and cationic polymer, and bone graft kit for manufacturing same | |
| Essawy et al. | Biocompatible chitosan in unique applications for tissue engineering | |
| ES2444090T3 (en) | Drug to promote tissue regeneration | |
| Han et al. | Natural materials as smart scaffolds for tissue engineering | |
| Thompson et al. | Natural Materials for Cell-Based Therapies | |
| Manoochehri et al. | Bioscaffold and Their Applications in Tissue Regeneration: Angiogenesis, Bone, Skin, and Nerve Tissue Regeneration | |
| Gosain et al. | Use of tissue glue: current status | |
| Zhu | A comparative histologic analysis of tissue engineered bone using BMSCs, alveolar bone cells, and periosteal cells | |
| Goldstein | Biomaterials for cell delivery: vehicles in regenerative medicine | |
| ZA et al. | Scaffold Selection for Tissue Engineering in Dentistry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140523 |